04th week of 2020 patent applcation highlights part 21 |
Patent application number | Title | Published |
20200024304 | METHOD OF PREPARING PEPTIDES COMPRISING A LIPOPHILICALLY MODIFIED LYSINE SIDE CHAIN - The present invention relates to a method of preparing a lysine side-chain modified peptide by solid phase peptide synthesis. | 2020-01-23 |
20200024305 | METHOD FOR PRODUCING PEPTIDE - An object of the present invention is to provide a novel solid phase peptide synthesis method for synthesizing a large amount of a peptide. Another object of the present invention is to provide a novel solid phase peptide synthesis method for synthesizing a high-purity long-chain peptide. Still another object of the present invention is to provide a novel solid phase peptide synthesis method causing fewer side reactions. The present invention relates to a method for producing a peptide, and the method comprises solid-phase synthesis of a peptide under stirring with a centrifugal stirrer having no impeller. | 2020-01-23 |
20200024306 | Method for Preparation of Peptides with psWANG Linker - The invention discloses a method for the preparation of a peptide by liquid phase coupling of two fragments, an N-terminal fragment and a C-terminal fragment of the desired peptide, wherein the C-terminal fragment is protected on its C-terminal COOH by a psWang linker; the method is demonstrated with liraglutide wherein the C-terminal fragment carries the Palmitoyl-Glu-OtBu residue on the Lys. | 2020-01-23 |
20200024307 | ANTIGENIC TRIPEPTIDES DERIVED FROM MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS S-TYPE STRAINS, DERIVATIVES AND USES THEREOF - The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to | 2020-01-23 |
20200024308 | PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES - The present technology provides peptides, methods of generating the peptides, and pharmaceutically acceptable salts of the peptides. In some embodiments, the peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH | 2020-01-23 |
20200024309 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS - Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 2020-01-23 |
20200024310 | NOVEL DEPSIPEPTIDE AND USES THEREOF - The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders. | 2020-01-23 |
20200024311 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE - The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e. Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates: | 2020-01-23 |
20200024312 | CELL-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT EFFECTORS AND CD8+ T-CELL EPITOPES - The present invention provides cell-targeting molecules which can deliver a CD8+ T-cell epitope cargo to the MHC class I presentation pathway of a target cell. The cell-targeting molecules of the invention can be used to deliver virtually any CD8+ T-cell epitope from an extracellular space to the MHC class I pathway of a target cell, which may be a malignant cell and/or non-immune cell. The target cell can then display on a cell-surface the delivered CD8+ T-cell epitope complexed with MHC I molecule. The cell-targeting molecules of the invention have uses which include the targeted labeling and/or killing of specific cell-types within a mixture of cell-types, including within a chordate, as well as the stimulation of beneficial immune responses. The cell-targeting molecules of the invention have uses, e.g., in the treatment of a variety of diseases, disorders, and conditions, including cancers, tumors, growth abnormalities, immune disorders, and microbial infections. | 2020-01-23 |
20200024313 | RECOMBINANT POLYPEPTIDE-ENRICHED CHLOROPLASTS OR ACCUMULATED LIPID PARTICLES AND METHODS FOR PRODUCING THE SAME IN ALGAE - The present disclosure relates to recombinant protein production in algal cells. In particular, the present disclosure provides methods for making recombinant polypeptides in association with accumulated lipid particles or chloroplasts. The methods involve producing the recombinant polypeptide as a fusion polypeptide with an oil body protein and the growth of the algal cells under non-homeostatic conditions to form accumulated lipid particles within the algal cells, wherein the algal lipid particles contain the fusion polypeptide. | 2020-01-23 |
20200024314 | ISOLATED B7-H4 SPECIFIC COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to B7-H4-specific compositions and methods of use thereof. | 2020-01-23 |
20200024315 | ANTIMICROBIAL PEPTIDES AND METHODS OF TREATING GRAM-NEGATIVE PATHOGENS - Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptide variants that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms | 2020-01-23 |
20200024316 | CACNA1H-DERIVED TUMOR ANTIGEN POLYPEPTIDE AND USE THEREOF - Provided are a tumor antigen polypeptide having the amino acid sequence as shown in SEQ ID NO: 2 or a variant thereof; a nucleic acid encoding the same; a nucleic acid construct, an expression vector, and a host cell containing the encoding nucleic acid; and an antigen presenting cell presenting the tumor antigen polypeptide on the cell surface and an immune effector cell thereof. Also provided is the use of the polypeptide, nucleic acid, antigen presenting cell or immune effector cell in the diagnosis, prevention and treatment of cancers. | 2020-01-23 |
20200024317 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-01-23 |
20200024318 | DUAL FUNCTION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME - The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases. | 2020-01-23 |
20200024319 | INTERLEUKIN-2 MUTEINS FOR THE EXPANSION OF T-REGULATORY CELLS - Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention. | 2020-01-23 |
20200024320 | VARIANTS OF ADRENOMEDULLIN AND CALCITONIN GENE-RELATED PEPTIDE AND METHODS OF USE - Variant peptides of calcitonin gene-related peptide alpha (αCGRP), calcitonin gene-related peptide beta (βCGRP), and adrenomedullin (AM) are disclosed, wherein the variant peptides have high binding affinity and agonistic or antagonistic activity for at least one receptor complex of CLR:RAMP1, CLR:RAMP2, and CLR:RAMP3. Also disclosed are methods of use of the variant peptides in therapeutic treatments. | 2020-01-23 |
20200024321 | EXPRESSION AND LARGE-SCALE PRODUCTION OF PEPTIDES - The invention provides a method for the large-scale preparation of small peptides using recombinant DNA technology. Overexpression of small peptides, such as liraglutide precursor, as concatemers, improves the overall efficiency of the process due to increased yields per batch of the biologically active peptide. Digestion of these concatemers by combinations of specific enzymes yields the desired peptide monomer in large quantities. More particularly, the invention relates to the production of recombinant peptide precursor of liraglutide | 2020-01-23 |
20200024322 | GIP/GLP1 CO-AGONIST COMPOUNDS - The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity. | 2020-01-23 |
20200024323 | TREATMENT OF NEUROPATHY WITH IGF-1-ENCODING DNA CONSTRUCTS AND HGF-ENCODING DNA CONSTRUCTS - The present invention relates to a method of treating neuropathy by administering DNA constructs, encoding a human IGF-1 isoform and a human HGF isoform. Further provided herein are various DNA constructs and pharmaceutical compositions including the DNA constructs that can be used for the combination therapy. The present invention provides a safe and effective way of treating neuropathic patients. | 2020-01-23 |
20200024324 | NEW PDL2 COMPOUNDS - The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2. | 2020-01-23 |
20200024325 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2020-01-23 |
20200024326 | TNF-TYPE RECEPTOR-LIGAND FUSION PROTEINS AND METHODS - Self-activating chimeric signaling proteins, and especially chimeric TNF family member ligand-receptor proteins are contemplated. In preferred methods, the chimeric protein comprises an extracellular portion of CD40L that is coupled via a flexible linker to CD40 such that the fusion protein, when expressed in an APC, is capable of folding back on itself and transmits a CD40-mediated signal as if it had been contacted by CD40L located on another cell. Advantageously, cells expressing such chimeric proteins contemporaneously with presentation of an antigen will enhance an immune reaction against the antigen. | 2020-01-23 |
20200024327 | OPTIMIZED FACTOR VIII GENE - The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. | 2020-01-23 |
20200024328 | COLLAGEN MIMICS - Novel collagen mimics are disclosed with a tripeptide unit having the formula (Xaa-Yaa-Gly) | 2020-01-23 |
20200024329 | METHODS FOR REGULATING ENDOGENOUS PRODUCTION OF LACTOFERRIN AND SUB-PEPTIDES THEREOF - The present disclosure relates to the composition of one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for upregulating production of lactoferrin or a sub-peptide of lactoferrin. Embodiments of the present disclosure can be used as a therapy or a treatment of adhesions or scarring. | 2020-01-23 |
20200024330 | BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODY - The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided | 2020-01-23 |
20200024331 | Single Domain Antibodies to Chikungunya Virus - Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Chikungunya Virus (CHIKV). | 2020-01-23 |
20200024332 | ANTIBODY - The invention relates to antibodies to | 2020-01-23 |
20200024333 | ENDOTROPHIN NEUTRALIZATION AND USE THEREOF - Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient. | 2020-01-23 |
20200024334 | Heterodimeric proteins and preparation method thereof - The present invention provides a heterodimeric protein comprising polypeptides that bind each other containing two CH3 regions, wherein amino acid mutations are introduced into CH3 region of the first polypeptide and CH3 region of the second polypeptide to form pairs of amino acids with polar interactions on their interaction interface, thereby forming a heterodimeric protein specifically. The heterodimeric protein of the present invention can prevent Fc mismatch, avoid homodimer formation, and has high yield and good stability. | 2020-01-23 |
20200024335 | FILAMIN B BINDING PROTEINS AND USES THEREOF - The present invention encompasses filamin B (FLNB) binding proteins. Specifically, the invention relates to antibodies to FLNB. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis or prostate cancer are also provided. | 2020-01-23 |
20200024336 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease. | 2020-01-23 |
20200024337 | AGENTS, USES AND METHODS - The present invention relates to a mouse antibody denoted m2E6, chimeric ch2E6, as well as to 3 humanized forms (2E6-HLD1, 2E6-HLD2 and 2E6-HLD3) and affinity matured forms of HLD1: 7A10, 5A1, 9D7, 9G11, 7C4, L3, 8D9, 9C12 or 6B6 to create higher affinity antibodies. | 2020-01-23 |
20200024338 | R-Spondin (RSPO) Surrogate Molecules - R-spondin (RSPO) surrogate compositions and methods for their use are provided. RSPO surrogates of the invention comprise (i) a specific binding domain for Ring Finger Protein 43 (RNF43) or Zinc and Ring Finger Protein 3 (ZNRF3) and (ii) a cell targeting domain More specifically, wherein the specific binding domain for RNF43 or ZNRF3 is an antibody fragment, and wherein the cell targeting domain is a cytokine. | 2020-01-23 |
20200024339 | COMPOSITIONS AND METHODS FOR MODULATING CELL SIGNALING - The present invention provides growth factor-directed agents (GDAs), which act as either antagonists or agonists of cell signaling, particularly in the TGF-beta and related extracellular matrix signaling pathways. Such GDAs include monoclonal antibodies, fusion proteins and novel polypeptide compositions and/or conjugates of these compositions. | 2020-01-23 |
20200024340 | ANTI-GM-CSF ANTIBODIES - The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 2020-01-23 |
20200024341 | LRP1 BINDING AGENTS AND USES THEREOF - Provided herein are agents that hind to binding domain I of LRP1 and mimic the activity of prosaposin in stimulating Tsp-1. Further provided herein are agents that inhibit the function (e.g., the ability to repress Tsp-1) of Protease, Serine 2 (PRSS2) by inhibiting the binding of PRSS2 to LRP1. Methods of using these agents in treating cancer are also provided. | 2020-01-23 |
20200024342 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF - The present disclosure provides chimeric antigen receptors, compostions, and methods thereof. In one embodiment the present disclosure provides a method of treating autoimmune diseases, asthma, and preventing or mediating organ rejection in a subject. | 2020-01-23 |
20200024343 | COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE - Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject. | 2020-01-23 |
20200024344 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA - A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists. | 2020-01-23 |
20200024345 | T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS - A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains. | 2020-01-23 |
20200024346 | MOLECULES WITH SPECIFICITY FOR CD79 AND CD22 - The present disclosure relates to multispecific molecule comprising a binding domain specific to the antigen CD22 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising the same and use of both in treatment, for example the treatment of autoimmune disease. | 2020-01-23 |
20200024347 | OR10H1 ANTIGEN BINDING PROTEINS AND USES THEREOF - The invention provides antigen binding proteins that bind to one or more extracellular domains of the human olfactory receptor 10H1 (OR10H1) or variants thereof, including antigen binding proteins which can modulate the expression, function, activity and/or stability of such receptor, as well as providing nucleic acids encoding such antigen binding proteins or components thereof. Methods for detecting OR10H1 or variants thereof in a sample, including diagnostic methods, using such antigen binding proteins are also provided. Uses of such antigen binding proteins, and nucleic acids encoding the same, in medicine are further provided. | 2020-01-23 |
20200024348 | ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | 2020-01-23 |
20200024349 | NOVEL BIOMARKERS FOR CANCER IMMUNOTHERAPY - The present invention provides a technique for predicting an effective patient prior to starting cancer immunotherapy. The present invention provides a method of using T cell receptor (TCR) diversity of a subject as an indicator of responsiveness of the subject to cancer immunotherapy. The present invention also provides a composition for treating cancer in a subject with high TCR diversity of T cells, comprising an immune checkpoint inhibitor. The present invention is also directed to a companion medicament using such TCR diversity. | 2020-01-23 |
20200024350 | ANTIBODIES AND METHODS OF USE THEREOF - Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination. | 2020-01-23 |
20200024351 | Compositions and Methods for the Treatment of Cancer - Methods of treating cancer with particular doses of anti-ICOS antibodies are provided. | 2020-01-23 |
20200024352 | ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES - The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation. | 2020-01-23 |
20200024353 | PROTEINS BINDING PSMA, NKG2D AND CD16 - Multi-specific binding proteins that bind PSMA, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. | 2020-01-23 |
20200024354 | BAFF SELECTIVE BINDING COMPOUNDS AND RELATED METHODS - The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas. | 2020-01-23 |
20200024355 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT - This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof. | 2020-01-23 |
20200024356 | Bispecific Anti-BCMA x Anti-CD3 Antibodies and Uses Thereof - B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides novel bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma. | 2020-01-23 |
20200024357 | COMPOSITIONS AND METHODS FOR TREATING CANCER - The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD | 2020-01-23 |
20200024358 | TRISPECIFIC ANTIGEN BINDING PROTEINS - Trispecific antigen-binding proteins including: a first binding domain capable of binding to a cell surface protein of a tumor cell; a second binding domain capable of binding to a cell surface immune checkpoint protein of the tumor cell; and a third binding domain capable of binding to a cell surface protein of an immune cell, are provided. Methods of making trispecific antigen-binding proteins are provided. | 2020-01-23 |
20200024359 | ANTI OLIGOSACCHARIDE ANTIBODY - An antigen-binding protein, or an antigen-binding fragment thereof that binds to a Lewis X type glycan on SLAMF7, comprising ( | 2020-01-23 |
20200024360 | PSMA BINDING AGENTS AND USES THEREOF - The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing. | 2020-01-23 |
20200024361 | ANTIBODY BINDING SPECIFICALLY TO MUC1 AND USE THEREOF - The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) and a use thereof and, more particularly, to an anti-MUC1 antibody or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for prevention or treatment of cancer, comprising the same conjugate or bispecific antibody, and a nucleic acid encoding the same antibody or an antigen-binding fragment thereof, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, an antibody binding specifically to MUC1 or an antigen-binding fragment thereof shows outstanding affinity and binding force to MUC1 and an antibody-drug conjugate in which the antibody or an antigen-binding fragment thereof is conjugated with a drug can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer. | 2020-01-23 |
20200024362 | ANTI-COAGULATION FACTOR XI ANTIBODY - Disclosed are antibodies thereof that bind to coagulation factor XI (FXI) and/or its activated form factor XIa (FXIa), or to fragments of FXI and/or FXIa, and compositions containing the antibodies. Also disclosed are methods of preparing the antibodies and use of the antibodies for treating and/or preventing coagulation associated conditions such as thrombosis and complications or conditions associated with thrombosis. | 2020-01-23 |
20200024363 | REDUCED VISCOSITY PROTEIN PHARMACEUTICAL FORMULATIONS - Described herein are therapeutic protein formulations comprising N-methyl pyrrolidone (NMP), methods related to reducing viscosity of pharmaceutical formulations and methods related to stabilizing pharmaceutical formulations using NMP. | 2020-01-23 |
20200024364 | DOSING REGIMENS FOR USE WITH PCSK9 INHIBITORS - The present invention provides methods for treating a PCSK9-mediated disease or a PCSK9-mediated condition. Specifically, the invention relates to methods comprising the administration of a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody or antigen binding protein, in the absence of a statin, to a subject in need thereof. | 2020-01-23 |
20200024365 | mRNA-ENCODED NANOBODY AND APPLICATION THEREOF - It relates to a nanobody encoded by a mRNA and an application thereof, and more particularly, to the field of nanobody drugs. In order to solve the problem above, the invention provides a novel concept and a method system for regulating an intracellular protein using an mRNA-encoding nanobody. The invention discloses a nanobody encoded by a mRNA, and encoding information carried by the mRNA is recognized, translated and expressed to a single-chain nanobody that can be bound to a targeting protein in a cell. By adopting the method, a function of a disease-related protein in a cell can be effectively and specifically interfered with, thus achieving the object of disease treatment. | 2020-01-23 |
20200024366 | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING - The present invention relates to antibodies with pH dependent binding to its antigen such that the affinity for antigen binding at physiological pH (i.e., pH 7.4) is greater than at endosomal pH (i.e., pH 6.0 or 5.5). In other words, the K | 2020-01-23 |
20200024367 | Hetero-Dimeric Immunoglobulins - The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same. | 2020-01-23 |
20200024368 | MICE EXPRESSING A LIMITED IMMUNOGLOBULIN LIGHT CHAIN REPERTOIRE - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. | 2020-01-23 |
20200024369 | COMPOSITIONS AND METHODS FOR CROSSLINKING FC RECEPTORS - The present invention provides compositions comprising molecules having multispecificity and method of their use. | 2020-01-23 |
20200024370 | SPLIT INTEIN COMPOSITIONS - Disclosed herein is a protein purification system and methods of using the system. In particular, disclosed is a split intein comprising an N-terminal intein segment, which can be immobilized, and a C-terminal intein segment, which has the property of being self-cleaving, and which can be attached to a protein of interest. Through the self-cleaving mechanism of the intein, the protein of interest can be purified. | 2020-01-23 |
20200024371 | REACTOR - A polymerization device that includes: a reaction vessel that houses a polymerization solution and in which a polymerization reaction is performed; a stirring blade that stirs the polymerization solution housed in the reaction vessel; a plurality of heat transfer pipes that transfer heat to the polymerization solution in order to start the polymerization reaction and cause the polymerization reaction to proceed, and that remove, from the polymerization solution, heat generated by the polymerization reaction; and a baffle arranged between a vessel wall of the reaction vessel and the heat transfer pipes. | 2020-01-23 |
20200024372 | ENZYME-ASSISTED ATRP PROCEDURES - Materials and methods for conducting an atom transfer radical polymerization in the presence of oxygen by interlocking enzymatic activities are provided herein. | 2020-01-23 |
20200024373 | MACRO-RAFT CHAIN TRANSFER AGENTS AS ANIONIC POLYMERIZATION TERMINATORS - The present invention relates to a compound of Formula (I): where {circle around (P)} R, R | 2020-01-23 |
20200024374 | COMPOSITION OF POLYETHYLENE GLYCOL MALEIMIDE DERIVATIVE AND POLYMERIZATION INHIBITOR - The present invention provides a composition of a polyethylene glycol maleimide derivative and a polymerization inhibitor. In particular, the present invention provides a composition of an 8-arm polyethylene glycol maleimide derivative and a phenolic polymerization inhibitor. The ingredient and content of the polymerization inhibitor in the composition are reasonably chosen, thereby significantly increasing stability of the polyethylene glycol maleimide derivative, effectively avoiding the undesirable effect of gel solidifying due to polymerization during storage and transportation, and extending a pot life and shelf life of a product thereof. | 2020-01-23 |
20200024375 | METHOD OF FORMING A MICROPHASE SEPARATED BLOCK COPOLYMER AND MICROPHASE SEPARATED BLOCK COPOLYMER - A method of forming a microphase separated block copolymer includes exposing a block copolymer to acid vapor under conditions effective to provide the microphase separated block copolymer. The block copolymer includes a first hydrophobic block and a second hydrophobic block that is acid-sensitive. The microphase separated block copolymer includes the first hydrophobic block and a hydrophilic block derived from the second hydrophobic block. Exposing the block copolymer to the acid vapor is conducted in the solid state. | 2020-01-23 |
20200024376 | BIOMODAL POLYMERIZATION CATALYSTS - Embodiments of the present disclosure directed towards bimodal polymerization catalysts. As an example, the present disclosure provides a bimodal polymerization catalyst system including a non-metallocene olefin polymerization catalyst and a zirconocene catalyst of Formula I: (Formula I) where each of R | 2020-01-23 |
20200024377 | BIS-LIGATED PHOSPHAGUANIDINE GROUP IV METAL COMPLEXES AND OLEFIN POLYMERIZATION CATALYSTS PRODUCED THEREFROM - Embodiments are directed to monophosphaguanidine ligands and the bis ligated metal-complexes formed therefrom, wherein the metal-ligand complexes are polymerization catalysts comprising the following structure (I). | 2020-01-23 |
20200024378 | Single-Site Catalyst Polyolefin Polymerization Process - Disclosed is a method for polymerizing olefins comprising passing a heterogeneous single-site catalyst to a solution or slurry polymerization reactor in the absence of pre-polymerization, wherein the polymerization reactor operates at a temperature of at least 50° C. The heterogeneous single-site catalyst may be suspended and/or dissolved in a solvent selected from the group consisting of oils, aliphatic hydrocarbons and mixtures thereof. Also, the heterogeneous single-site catalyst may be passed to the polymerization reactor at a velocity of greater than 1 m/s or 3 m/s. | 2020-01-23 |
20200024379 | PROCESS FOR THE PREPARATION OF SYNDIOTACTIC 1,2-POLYBUTADIENE IN THE PRESENCE OF A CATALYTIC SYSTEM COMPRISING A PYRIDYL IRON COMPLEX - Process for the preparation of syndiotactic 1,2-polybutadiene comprising polymerising 1,3-butadiene in the presence of a catalytic system comprising: —at least one pyridyl iron complex having the general formula (I), in which: —R | 2020-01-23 |
20200024380 | CAPPED MULTI- OR DUAL-HEADED COMPOSITIONS USEFUL FOR CHAIN SHUTTLING AND PROCESS TO PREPARE THE SAME - The present disclosure relates to a capped, multi- or dual-headed chain composition comprising derivatives of a strained olefin. The present disclosure further relates to a process for synthesizing the capped, multi- or dual-headed composition by using an organometallic compound and a co-catalyst in the presence of a catalyst precursor and a strained olefm. The present disclosure further relates to use of the compositions, as well as the process to make the same, in olefin polymerization. | 2020-01-23 |
20200024381 | PRODUCTION OF LIGHT-TRANSMISSIVE OBJECTS BY ADDITIVE MANUFACTURING - Provided herein is a method of making a clear or translucent object by additive manufacturing, comprising (a) providing a clear or translucent light polymerizable resin, the resin comprising: (i) light-polymerizable monomers, prepolymers, or a combination thereof; (ii) a photoinitiator; and (iii) a polysubstituted linear polyacene ultraviolet light absorbing compound which compound is polysubstituted with bromo, chloro, —Se—R′, —S—R′ or combinations thereof, where each R′ is independently selected from alkyl, aryl, and arylalkyl; and then (b) producing by stereolithography with ultraviolet light a clear or translucent object from said light polymerizable resin. | 2020-01-23 |
20200024382 | NANOPARTICLES COMPLEXED WITH FUNCTIONALIZABLE ENHANCED AFFINITY LIGANDS AND USE THEREOF - Disclosed are functionalizable ligands, nanoparticles, preferably nanocrystals, complexed with ligands and their use for bio-imaging. A nano material includes a nanoparticle and at least one copolymer ligand. A ligand which is a copolymer of general formula (I): H-P[(A)x-co-(B)y]n-L-R. | 2020-01-23 |
20200024383 | Modified Conjugated Diene Polymer, Modified Conjugated Diene Polymer Composition, Tire, and Method for Producing Modified Conjugated Diene Polymer - A modified conjugated diene polymer satisfying the following conditions (I) to (IV):
| 2020-01-23 |
20200024384 | POLYMER, ORGANIC LAYER COMPOSITION AND METHOD OF FORMING PATTERNS - A polymer, an organic layer composition including the polymer, and a method of forming a pattern using the organic layer composition, the polymer including a reaction product of a first compound represented by Chemical Formula 1 and a second compound represented by Chemical Formula 2: | 2020-01-23 |
20200024385 | HYDROCARBON-BASED POLYMERS BEARING TWO ALKOXYSILANE END GROUPS - Hydrocarbon-based polymer of formula (1) bearing alkoxysilane end groups: | 2020-01-23 |
20200024386 | HIGH PERFORMANCE WIDE-BANDGAP POLYMERS FOR ORGANIC PHOTOVOLTAICS - A copolymer comprising a repeat unit A, wherein repeat unit A comprises | 2020-01-23 |
20200024387 | POLYMERS CONTAINING AROMATIC DICARBOXYLIC ACID - A process is provided for making a polymer comprising providing a mixture of at least one furandicarboxylic acid, at least one diol, and at least one C2-C3 dicarboxlic acid, ester derivatives of C2-C3 dicarboxylic acid, hydroxy fatty acid or ester derivative of a hydroxy fatty acid; adding a catalyst and processing said mixture at reaction conditions until a polymer product is produced. The polymer consists of random units based upon the starting materials that are used. | 2020-01-23 |
20200024388 | POLYESTER RESIN COMPOSITION, AND MOLDING OF POLYESTER RESIN AND METHOD FOR PRODUCING SAME - A polyester resin composition includes a copolymer of a polycarboxylic acid component and a polyol component. The polycarboxylic acid component includes terephthalic acid and/or a derivative thereof The polyol component includes ethylene glycol and/or a derivative thereof and 2,2-dimethyl-1,3-propanediol and/or a derivative thereof. A content by percentage of 2,2-dimethyl-1,3-propanediol and/or the derivative thereof is 27 mol % to 55 mol % based on the total amount of the polyol component. The composition has an intrinsic viscosity of 0.5 dl/g to 0.6 dl/g. | 2020-01-23 |
20200024389 | COMPOSITIONS FOR THE PRODUCTION OF OBJECTS USING ADDITIVE MANUFACTURING - This invention relates to a filament build material for a three-dimensional printer, where the filament comprises a polymeric material that includes units of a diacid component and units of a glycol component. The units of the diacid component includes from about 40 mole % to about 60 mole % of units derived from a first diacid and from about 40 mole % to about 60 mole % of units derived from a second diacid, wherein the first diacid is terephthalic acid and the second diacid is chosen from isophthalic acid, a cyclohexanedicarboxylic acid, a naphthalenedicarboxylic acid, a stilbenedicarboxylic acid, or a combination thereof. | 2020-01-23 |
20200024390 | Flame Retardant Lactide Monomors for Polylactide Synthesis - A process of forming a flame retardant polylactide includes forming a flame retardant lactide monomer. The process also includes forming a lactide feedstock that includes at least the flame retardant lactide monomer. The process further includes polymerizing the lactide feedstock to form a flame retardant polylactide. | 2020-01-23 |
20200024391 | DEGRADABLE POLYETHYLENE GLYCOL DERIVATIVE HAVING DISULFIDE LINKER - To provide a degradable polyethylene glycol derivative in which polyethylene glycol chains are linked by a disulfide linker capable of accurately controlling the degradation rate under different reductive environments in the living body, and whose division rate into a polyethylene glycol chain of low molecular weight in the living body is able to be accurately controlled. A degradable polyethylene glycol derivative represented by formula (1). R | 2020-01-23 |
20200024392 | POLYMERIC MATERIALS - A polymeric material has a repeat unit of formula —O-Ph-O-Ph-CO-Ph- I and a repeat unit of formula —O-Ph-Ph-O-Ph-CO-Ph- II wherein Ph represents a phenylene moiety; wherein the repeat units I and II are in the relative molar properties I:II of from 65:35 to 95:5; wherein log | 2020-01-23 |
20200024393 | POLYMERS AND PROCESS FOR THEIR MANUFACTURE - There is disclosed polymers, a process for manufacturing polymers and uses of the polymers. The polymers are polyaryl ether ketones and the process includes a nucleophilic polycondensation of a bisphenol with an organic dihalide compound in a reaction mixture comprising sodium carbonate and potassium carbonate, in an aromatic sulfone solvent, at a reaction temperature rising to a temperature from 290° C. to 320° C. immediately prior to the addition of a salt to the reaction mixture, wherein the molar ratio of the salt to potassium carbonate is from 6.0 to 10.0. Further organic dihalide compound is added to the reaction mixture wherein the molar ratio of further organic dihalide compound to bisphenol is from 0.009 to 0.035. The resulting reaction mixture is maintained at a temperature at from 290° C. to 320° C. for from 20 to 180 minutes and then the resulting reaction mixture is cooled and the PAEK recovered. | 2020-01-23 |
20200024394 | FEEDSTOCK AND METHODS FOR ADDITIVE MANUFACTURING OF RADIATION SHIELDING PARTS - A melt-processable consumable material configured as a feedstock for use in an additive manufacturing system includes a polymeric matrix comprising one or more polyaryletherketones, wherein the polymeric matrix comprises between about 10 wt % and about 50 wt % of the total weight of the feedstock. The material includes radiation shielding particles dispersed within the polymer matrix wherein the radiation shielding particles comprise between about 50 wt % and less than 90 wt % of the total weight of the feedstock. | 2020-01-23 |
20200024395 | SEMI-CRYSTALLINE POLYAMIDE COMPOSITION HAVING A HIGH GLASS TRANSITION TEMPERATURE AND A HIGH MELTING TEMPERATURE FOR A THERMOPLASTIC MATERIAL, PRODUCTION METHOD THEREOF AND USES OF SAME - The invention relates to a composition for a thermoplastic material comprising:
| 2020-01-23 |
20200024396 | MONOMERIC BALANCE CONTROL IN THE PREPARATION OF PRECURSORS FOR POLYAMIDATION PROCESSES - Disclosed is a method for measuring and/or controlling salt balance in a feed to a condensation polymerization process for making nylon. The method employs Raman spectroscopy. | 2020-01-23 |
20200024397 | TETRACARBOXYLIC DIANHYDRIDE, CARBONYL COMPOUND, POLYIMIDE PRECURSOR RESIN, AND POLYIMIDE - A tetracarboxylic dianhydride includes: at least one acid dianhydride (A) selected from the group consisting of compounds each having an endo/exo type three-dimensional structure represented by a particular general formula and their enantiomeric compounds each having an exo/endo type three-dimensional structure; and/or an acid dianhydride (B) having an endo/endo type three-dimensional structure represented by a particular general formula, wherein a content of the acid dianhydride (B) in a total amount of the acid dianhydrides (A) and (B) is 30 to 100% by mole in a mole ratio. | 2020-01-23 |
20200024398 | METHODS OF MANUFACTURE FOR POLYETHERIMIDE - A method of making polyetherimide includes: reacting a diamine having four bonds between the amine groups, 4-halophthalic anhydride and 3-halophthalic anhydride at an imidization reaction temperature and pressure in the presence of a solvent and a polymer additive to produce a mixture including 3,3′-bis(halophthalimide), 3,4′-bis(halophthalimide), 4,4′-bis(halophthalimide), solvent, and the polymer additive wherein the molar ratio of 3-halophthalic anhydride to 4-halophthalic anhydride is 95:05 to 60:40; reacting the mixture with an alkali metal salt of a dihydroxy aromatic compound to produce a polyetherimide having a cyclics content less than 6 weight percent, based on the total weight of the polyetherimide, a glass transition temperature greater than or equal to 220° C., and a weight average molecular weight greater than or equal to 25,000 Daltons; wherein the polymer additive dissolves in the solvent at the imidization reaction temperature and pressure. | 2020-01-23 |
20200024399 | LIQUID CRYSTAL DISPLAY DEVICE - The present invention provides a liquid crystal display device with a high degree of freedom in molecular structure design of an alignment film and with reduced image sticking. The liquid crystal display device includes a pair of substrates; a liquid crystal layer held between the substrates; an alignment film disposed on a liquid crystal layer side surface of at least one of the substrates; and a polymer layer disposed between the liquid crystal layer and the alignment film, the alignment film containing a first polymer containing at least one structure represented by the following formula (1) in a side chain, | 2020-01-23 |
20200024400 | METHODS OF MANUFACTURE FOR POLYETHERIMIDE - A method of making a polyetherimide comprising reacting a diamine having four bonds or more between the amine groups, 3,3′-bisphenol A dianhydride, and 4,4′-bisphenol A dianhydride to form a polyetherimide having a cyclics content less than 1 weight percent (wt %), a glass transition temperature greater than or equal to 213° C., and a weight average molecular weight greater than or equal to 25,000 Daltons, wherein the molar ratio of 3,3′-bisphenol A dianhydride to 4,4′-bisphenol A dianhydride is 98:02 to 10:90. | 2020-01-23 |
20200024401 | POLY(AMIDE-IMIDE) COPOLYMER COMPOSITION AND COLORLESS AND TRANSPARENT POLY(AMIDE-IMIDE) FILM COMPRISING THE SAME - A poly(amide-imide) copolymer composition comprising an imide of a polyamic acid and an ultraviolet stabilizer, and a colorless and transparent poly(amide-imide) film including the composition. The poly(amide-imide) copolymer composition according to the present disclosure makes it possible to provide a poly(amide-imide) film exhibiting excellent scratch resistance, UV shielding property, and UV weather resistance while being colorless and transparent. This film can be suitably used as a cover film of various flexible or foldable devices. | 2020-01-23 |
20200024402 | METHOD FOR PRODUCING GRANULAR POLYARYLENE SULFIDE AND GRANULAR POLYARYLENE SULFIDE - To provide a method for producing granular polyarylene sulfide (hereinafter, PAS), the method capable of providing granular PAS having high particle strength and low melt viscosity in high yield without using special additives and the like; and granular PAS. | 2020-01-23 |
20200024403 | Compositions and Methods for Injectable Composition for an Accommodating Intraocular Lens - The present disclosure relates to injectable compositions and methods of making injectable compositions of moisture curing siloxane polymers for forming accommodating intraocular lenses. In certain embodiments, the moisture curing siloxane polymers are comprised of an organosilicon compound and a hydrolytically sensitive siloxane moiety and have a specific gravity of greater than about 0.95, a number average molecular weight (M | 2020-01-23 |